Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
01 09 2020
01 09 2020
Historique:
pubmed:
31
5
2020
medline:
4
9
2020
entrez:
31
5
2020
Statut:
ppublish
Résumé
Around the world, several dose regimens of hydroxychloroquine have been used for COVID-19 infection treatment, with the objective of identifying a short-term course. Hydroxychloroquine was found to decrease the viral replication in a concentration-dependent manner in vitro and to be more active when added prior to the viral challenge. A loading dose is used to rapidly attain a target drug concentration, which is usually considered as approximately the steady-state concentration. With a loading dose, the minimum effective concentration is reached much more rapidly than when using only the maintenance dose from the start. Thus, we propose a hydroxychloroquine sulphate dose regimen of 400 mg twice daily at Day 1 then 400 mg once daily from Day 2 to Day 10. We aim to evaluate this in the C-20-15 DisCoVeRy trial.
Identifiants
pubmed: 32473020
pii: 5849074
doi: 10.1093/jac/dkaa191
pmc: PMC7314033
doi:
Substances chimiques
Hydroxychloroquine
4QWG6N8QKH
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2376-2380Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
Br J Clin Pharmacol. 1988 Sep;26(3):303-13
pubmed: 3179169
Chirality. 1994;6(4):360-4
pubmed: 8068494
Cell Discov. 2020 Mar 18;6:16
pubmed: 32194981
Best Pract Res Clin Rheumatol. 2004 Apr;18(2):233-47
pubmed: 15121042
J Infect. 2019 Mar;78(3):178-186
pubmed: 30653985
Br J Clin Pharmacol. 1989 Jun;27(6):771-9
pubmed: 2757893
Arthritis Rheum. 1999 Feb;42(2):357-65
pubmed: 10025931
J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670
pubmed: 32196083
Br J Clin Pharmacol. 1995 Aug;40(2):127-33
pubmed: 8562294
Am J Med. 1983 Jul 18;75(1A):11-8
pubmed: 6408923
Biopharm Drug Dispos. 1988 Nov-Dec;9(6):513-26
pubmed: 3067757